Aura Biosciences, Inc. (AURA)
After hours:
| Previous close | 7.54 |
| Open | 7.68 |
| Bid | 7.29 x 300 |
| Ask | 7.35 x 200 |
| Day's range | 7.31 - 7.79 |
| 52-week range | 5.99 - 13.50 |
| Volume | |
| Avg. volume | 180,606 |
| Market cap | 373.479M |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.80 |
- GuruFocus.com
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
Insights into Aura's Financial Health and Strategic Progress in Clinical Trials
GlobeNewswireAura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, t
- GlobeNewswire
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.Fireside Chat at 9:00 a.m. ET. TD Cowen 5th Annual Oncolo
